James Berenson, MD, Institute for Myeloma and Bone Cancer Research, West Hollywood, CA, outlines the mechanism of action of belantamab mafodotin, an anti-B cell maturation antigen (BCMA) antibody-drug conjugate indicated for relapsed/refractory multiple myeloma. Belantamab selectively binds to BCMA and the conjugated monomethyl auristatin F (MMAF) mediates myeloma cell death. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.